Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The companys preclinical product candidates include BPX-601, a chimeric antigen receptor (CAR-T) product candidate for treating solid tumors expressing the prostate stem cell antigen; BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma; and BPX-401, a CAR-T product candidate for the treatment of hematological cancers that express the CD19 antigen. The company has a research collaboration agreement with Holland's Leiden University Medical Center to discover and validate natural high-affinity T cell receptor product candidates targeting various cancers. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.